Personalis (PSNL) Q1 2026 earnings review
Market Share at Any Cost: Volumes Surge as Margins Evaporate
Personalis is executing its 'Win-in-MRD' strategy with ruthless precision, but the financial toll is severe. Q1 2026 clinical test volumes exploded 258% YoY to 7,815, driving clinical revenue up to $1.4M. However, total revenue declined 25% YoY to $15.5M due to the planned runoff of legacy biopharma and enterprise contracts. Because the company is actively processing thousands of tests before securing broad reimbursement, Q1 gross margin collapsed to a staggering 1.8% (down from 35% a year ago). With a new Medicare win in lung cancer and $233M in cash, management is betting that short-term financial pain will build an insurmountable long-term moat in the ultrasensitive MRD space.
🐂 Bull Case
The NeXT Personal test is gaining massive traction. 26% sequential volume growth in a seasonally weak Q1 proves the value of the Tempus commercial partnership. Ordering physicians are sticky and volumes are compounding.
Securing Medicare coverage for lung cancer on the heels of breast cancer validates the clinical utility of their 1-part-per-million sensitivity. As these tests transition from unreimbursed to paid, gross margins will violently expand.
🐻 Bear Case
Gross margin dropped to 1.8% in Q1. The company is effectively paying to process tests for market share. Until more indications are reimbursed, the volume growth is a liability on the P&L.
Total revenue contracted 25% YoY as legacy enterprise (Natera) and biopharma projects wind down. The new MRD revenue stream ($1.4M) is not yet large enough to offset the loss of the old business ($5.1M drop YoY).
⚖️ Verdict: ⚪
Neutral. The operational execution is flawless—they are capturing the MRD market exactly as promised. However, the 1.8% gross margin and accelerating cash burn mean this stock remains a high-risk 'show-me' story strictly dependent on Medicare pricing and coverage expansion.
Key Themes
Explosive Clinical Volume Growth
Clinical test delivery is accelerating dramatically. Q1 processed 7,815 tests, a 258% YoY increase and a 26% sequential jump. The company is actively front-loading adoption ahead of reimbursement, utilizing its Tempus partnership to build a massive installed base of ordering oncologists.
Medicare Coverage Expands to Lung Cancer
Personalis secured Medicare coverage for Stage I to III NSCLC surveillance in Q1, marking its second major coverage decision in six months (alongside breast cancer). This is the crucial catalyst needed to flip thousands of currently unreimbursed tests into high-margin revenue generators.
Gross Margin Total Collapse
The strategy to capture market share ahead of reimbursement led to a severe break in margin trend. Gross margin imploded to 1.8% in 26Q1 ($281K gross profit on $15.5M revenue), down from 35.0% a year ago. While management guides for 15-20% for the full year, the Q1 run-rate exposes how expensive the 'Win-in-MRD' volume strategy truly is.
Innovation: Real-Time Variant Tracker
The company launched an early access feature for NeXT Personal that longitudinally tracks resistance and targetable mutations during routine disease monitoring. This shifts the test from a simple binary 'yes/no' for recurrence to a therapeutic optimization tool, significantly increasing its stickiness with oncologists.
Legacy Revenue Drag Masking Core Growth
Total revenue is reversing, down 25% YoY ($15.5M vs $20.6M). While clinical revenue grew 5x YoY, it is still only $1.4M—too small to fill the gap left by the intentional decline in non-core legacy sequencing and enterprise contracts (Natera/Moderna roll-offs).
Opportunistic ATM Dilution Despite High Cash
Despite entering the year with $240M in cash (a guided 2.5-year runway), management utilized their At-The-Market (ATM) facility in Q1 to raise $21.0M at a weighted average of $10.00 per share. The Q1 net loss widened to $30.0M. The ongoing dilution suggests management wants an extra cash buffer as the margin squeeze intensifies.
Other KPIs
Accelerating deterioration. Loss widened significantly from $15.8M in 25Q1 and $23.7M in 25Q4. The expansion is driven entirely by the collapse in gross profit as test volumes scale without matching reimbursement, alongside a $5.6M YoY increase in SG&A expenses.
Stable sequentially compared to $240.0M at the end of FY25, but only because it was propped up by $21M in ATM equity issuance. True operating cash burn for the quarter was closer to ~$28M, aligning with the $100M full-year burn guidance.
Accelerating. Up 366% YoY from $0.3M in 25Q1, and tracking well against the FY26 guidance of $10-11M. As Medicare claims for Breast and Lung cancer begin to process in subsequent quarters, this line item is expected to ramp steeply.
Guidance
Accelerating. Implies roughly 13.5% YoY growth over FY25's ~$69.6M. With Q1 coming in at $15.5M, the guidance requires a significant sequential ramp (averaging ~$21M per quarter for the rest of the year) heavily dependent on clinical reimbursement turning on.
Accelerating. Represents a massive 171% YoY growth at the midpoint compared to ~16,233 in FY25. With 7,815 delivered in Q1, the company is slightly behind the implied ~11,000 quarterly run-rate, but historical adoption curves suggest back-half weighting.
Accelerating. Implies a 5x increase YoY. At 44,000 total tests, this assumes an average blended realization rate of roughly $238 per test across the entire volume base, highlighting that the vast majority of tests will remain unreimbursed this year.
Reversing. Down from FY25's 22.7%, but implies a drastic acceleration from Q1's abysmal 1.8%. Management is implicitly guiding that Medicare payments will start offsetting the heavy volume COGS in Q2-Q4.
Accelerating loss. Widening from FY25's $81.3M loss. This represents the peak investment year for establishing market dominance ahead of broad IO and CRC reimbursement decisions.
Key Questions
Margin Bridge from Q1 to FY26 Guidance
Gross margin was 1.8% in Q1, yet full-year guidance is 15-20%. What specific assumptions regarding the timing of Medicare cash collections for Breast and Lung indications are required to hit the midpoint of this margin guidance?
ATM Utilization Rationale
Management previously stated the $240M cash balance provided a 2.5-year runway. Why tap the ATM in Q1 at $10.00 per share? Is this simply opportunistic, or is cash burn running hotter than the modeled $100M?
Colorectal Cancer (CRC) Reimbursement Timeline
With the compelling 100% negative predictive value data presented at AACR, what are the remaining hurdles and expected timeline for submitting a MolDX dossier for CRC, the largest single MRD market?
Biopharma Demand vs Legacy Runoff
Non-clinical revenue was $14.1M in Q1. How much of this is high-value prospective biopharma MRD testing versus the runoff of legacy translational/population sequencing, and when does the MRD portion eclipse the legacy drag?